Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) reported pivotal Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma.
Daraxonrasib reduced risk of death by 60% (HR 0.40), doubled median OS to 13.2 vs ~6.6–6.7 months, improved PFS and response rates, and showed a generally manageable safety profile versus chemotherapy. The company plans global regulatory filings and has an FDA-authorized expanded access program.
AI-generated analysis. Not financial advice.
Positive
- Median overall survival 13.2 months vs 6.6–6.7 months with chemotherapy (HR 0.40)
- Progression-free survival 7.2–7.3 months vs 3.5–3.6 months (HR 0.45–0.49)
- Objective response rate ~32–33% vs ~11–12% with standard chemotherapy
- Grade ≥3 treatment-related adverse events 43.6% vs 57.5% with chemotherapy
- Treatment discontinuation for adverse events 1.2% vs 11.2% with chemotherapy
- Plans for global regulatory submissions, including a U.S. FDA New Drug Application
Negative
- Grade ≥3 treatment-related adverse events still occurred in 43.6% of daraxonrasib-treated patients
- One Grade 5 treatment-related pneumonitis case (0.4%) reported with daraxonrasib
- Median follow-up 8.5 months at data cutoff may limit long-term outcomes insight
Key Figures
Market Reality Check
Peers on Argus
RVMD is up 1.84% while close peers are mostly flat to down (e.g., MDGL -3.36%, ROIV -1.05%), pointing to a stock-specific reaction to the daraxonrasib Phase 3 data.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Phase 1/2 data NEJM | Positive | -5.7% | Phase 1/2 daraxonrasib data in PDAC and positive topline RASolute 302 OS benefit. |
| Apr 21 | Phase 1/2 AACR update | Positive | -4.4% | Updated first-line daraxonrasib Phase 1/2 data supporting ongoing Phase 3 evaluation. |
| Apr 21 | ASCO plenary preview | Positive | +1.8% | Announcement of upcoming ASCO plenary with detailed Phase 3 RASolute 302 results. |
| Apr 13 | Topline Phase 3 data | Positive | +41.4% | Topline RASolute 302 showing strong OS benefit vs chemotherapy in mPDAC. |
| Apr 02 | New Phase 3 trial start | Positive | +0.5% | Initiation of RASolute 303 Phase 3 trial in first-line metastatic pancreatic cancer. |
Clinical trial news has generally been positive but produced mixed reactions, with two sizable selloffs and three gains, including one large spike on earlier RASolute 302 topline results.
Over the past few months, RVMD has repeatedly highlighted daraxonrasib’s progress in metastatic pancreatic cancer. Earlier clinical updates and topline Phase 3 RASolute 302 data on Apr 13 drove a 41.35% move, while subsequent Phase 1/2 and presentation announcements on Apr 21 and May 6 were followed by modest declines. Today’s detailed Phase 3 plenary ASCO presentation and NEJM publication extend this sequence of escalating evidence around daraxonrasib’s efficacy and safety profile.
Historical Comparison
In the past months, RVMD’s five clinical-trial releases averaged a 6.73% move. Today’s modest 1.84% gain is smaller than prior reactions to daraxonrasib data.
Clinical updates show a progression from initiating Phase 3 programs through topline RASolute 302 success, to detailed plenary and NEJM presentations reinforcing daraxonrasib’s role in metastatic pancreatic cancer.
Market Pulse Summary
This announcement details mature Phase 3 RASolute 302 results, with daraxonrasib showing broad survival, response, and quality-of-life advantages over chemotherapy in metastatic pancreatic cancer. Prior topline and Phase 1/2 updates on Apr 13, Apr 21, and May 6 established a trajectory toward registrational filings. Investors may track global regulatory submissions, the expanded access program, and outcomes from related Phase 3 trials such as RASolute 303 as key future milestones.
Key Terms
progression-free survival medical
overall survival medical
hazard ratio medical
objective response rates medical
pneumonitis medical
neutropenia medical
thrombocytopenia medical
expanded access treatment protocol regulatory
AI-generated analysis. Not financial advice.
Results simultaneously published in The New England Journal of Medicine
REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results will be presented during a late-breaking Plenary Session (LBA5) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting at 3:21 p.m. CDT today and were published today in The New England Journal of Medicine.
RAS, a key growth control switch in human cells, is the primary oncogenic driver of PDAC, a disease that is typically characterized by excessive RAS(ON) signaling in tumors with or without a mutant allele of RAS. Daraxonrasib is the first investigational agent in a novel class of RAS(ON) multi-selective inhibitors designed to address a diverse and broad spectrum of RAS variants. In the randomized Phase 3 RASolute 302 trial, once-daily oral daraxonrasib demonstrated unprecedented improvements in overall survival (OS) and progression-free survival (PFS) compared to standard of care cytotoxic chemotherapy in patients with previously treated metastatic PDAC, with or without an identified tumor RAS mutation. All primary and key secondary endpoints of the trial were met. Daraxonrasib exhibited a manageable safety profile and patients treated with daraxonrasib reported significantly delayed deterioration in cancer-related pain, overall global health status and quality of life, compared to those treated with chemotherapy.
“Revolution Medicines has been singularly focused on developing bold new targeted medicines for treating patients with RAS-driven cancers, which are some of the most aggressive and difficult-to-treat diseases in oncology. The data from the Phase 3 RASolute 302 trial clearly validate our pioneering, science-driven approach and add to the growing body of evidence underscoring the broad potential of RAS(ON) inhibition that we are testing across pancreatic cancer and other RAS-driven cancers,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines.
“Daraxonrasib significantly elevates the survival bar in the treatment of one of the deadliest human cancers, while better preserving quality of life compared to chemotherapy. In this trial, daraxonrasib redefined treatment expectations in previously treated metastatic pancreatic cancer by reducing the risk of death by
"These results from the Phase 3 RASolute 302 trial of daraxonrasib represent a major milestone for patients facing metastatic pancreatic cancer,” said Brian M. Wolpin, M.D., M.P.H., director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, professor of medicine at Harvard Medical School, and principal investigator for the RASolute 302 trial. “For many patients, second line chemotherapy provides modest benefits, and new treatments delivering more durable tumor control have been urgently needed. In this global randomized trial, daraxonrasib, an oral RAS(ON) inhibitor, doubled median overall survival compared to standard of care chemotherapy for patients with previously treated metastatic pancreatic cancer. Importantly, this survival benefit was achieved with a generally manageable safety profile, highlighted by the low rate of treatment discontinuation due to treatment-related side effects. These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer, and support a new paradigm where RAS(ON) inhibition enters standard of care for patients with previously treated metastatic pancreatic adenocarcinoma."
Summary of Phase 3 RASolute 302 Clinical Trial Results
The trial enrolled 500 patients with previously treated metastatic PDAC, randomized to receive once-daily oral daraxonrasib (n=248) or investigator’s choice of four different cytotoxic chemotherapy regimens (n=252), which represent standard of care across the globe. At the February 10, 2026 data cutoff, median follow-up was 8.5 months (range, 3.2–15.9). The trial met all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful improvements versus chemotherapy in both the RAS G12 mutant population (daraxonrasib n=228; chemotherapy n=231) and the overall, or intent-to-treat (ITT), population, which included patients with or without an identified tumor RAS mutation.
Daraxonrasib resulted in a
Daraxonrasib was generally well tolerated with a manageable safety profile and no unexpected safety findings. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in
The RASolute 302 trial also evaluated patient-reported outcomes as an important secondary outcome, given the high symptom burden that patients with metastatic PDAC experience. Daraxonrasib demonstrated a statistically significant and clinically meaningful delay in the time to deterioration in pain, global health status and quality of life when compared to standard of care chemotherapy. In the ITT population, the HR for time to deterioration in pain was 0.51 (
Revolution Medicines intends to submit these data to global regulatory authorities, including to the U.S. Food and Drug Administration (FDA) as part of a New Drug Application under a Commissioner’s National Priority Voucher. In addition, the U.S. FDA recently authorized the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for eligible patients. Additional details on the daraxonrasib EAP are available here.
Company Webcast
Revolution Medicines will host a webcast on May 31, 2026, at 6:00 p.m. Central Time (7:00 p.m. Eastern Time). To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About the RASolute 302 Clinical Trial
RASolute 302 (NCT06625320) is a global, randomized Phase 3 registrational clinical trial designed to evaluate the efficacy and safety of daraxonrasib as a monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). In the trial, patients were randomized to receive either an oral dose of 300 mg daraxonrasib once daily or investigator’s choice of four different cytotoxic chemotherapy regimens, which represent standard of care across the globe. The trial enrolled patients with metastatic PDAC harboring a wide range of RAS variants, including those with RAS G12 mutations (such as G12D, G12V, and G12R), as well as patients without an identified tumor RAS mutation (wild type).
The primary endpoints of the RASolute 302 trial were progression-free survival (PFS), as assessed by a Blinded Independent Central Review according to RECIST 1.1, and overall survival (OS) in patients with tumors harboring RAS G12 mutations. Secondary endpoints included PFS and OS in all enrolled patients (the intent-to-treat population) encompassing patients with and without identified tumor RAS mutations, as well as objective response rate, duration of response, and patient-reported quality of life.
About Daraxonrasib
Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent inhibitor that is not approved by any regulatory authority, including in the United States or Europe. The U.S. Food and Drug Administration (FDA) granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation for the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring G12 mutations. In addition, daraxonrasib was selected for the FDA Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the development and review of therapies aligned with U.S. national health priorities.
Daraxonrasib is designed to target cancers driven by a broad range of common RAS genotypes, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. In addition to the RASolute 302 trial, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC and metastatic RAS mutant NSCLC.
Daraxonrasib works by suppressing RAS signaling through inhibition of the interaction between both wild-type and mutant RAS(ON) proteins and their downstream effectors.
About Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma
Pancreatic cancer is one of the most lethal malignancies, characterized by its typically late-stage diagnosis, resistance to standard chemotherapy, and high mortality rate. In the U.S., recent estimates indicate that annually approximately 60,000 people will be diagnosed with pancreatic cancer, and about 50,000 people will die from this aggressive disease.1
Due to the lack of early symptoms and detection methods, approximately
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition; daraxonrasib becoming a standard of care; treatment practices for pancreatic cancer; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.
Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” "believe," "estimate," "expect," "plan," “potential,” “project,” “up to,” "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Annual Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 6, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
References
1 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
2 Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1);91. doi:10.1038/s41698-022-00334-z.
3 Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014
4 American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. Accessed May 2026.
